Multifocal lymphangioendotheliomatosis
| Multifocal lymphangioendotheliomatosis | |
|---|---|
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Red skin lesions, gastrointestinal bleeding |
| Complications | Anemia, heart failure |
| Onset | Infancy |
| Duration | Chronic |
| Types | N/A |
| Causes | Unknown |
| Risks | N/A |
| Diagnosis | Clinical evaluation, biopsy |
| Differential diagnosis | N/A |
| Prevention | N/A |
| Treatment | Supportive care, medications |
| Medication | N/A |
| Prognosis | Variable |
| Frequency | N/A |
| Deaths | N/A |
Multifocal lymphangioendotheliomatosis (MLE) is a rare vascular disorder characterized by the presence of multiple red skin lesions and potential internal organ involvement, particularly the gastrointestinal tract. It is primarily observed in infants and young children.
Presentation[edit]
Patients with multifocal lymphangioendotheliomatosis typically present with multiple red or purple skin lesions that are often mistaken for hemangiomas. These lesions are usually present at birth or appear shortly thereafter. In addition to cutaneous manifestations, patients may experience gastrointestinal bleeding, which can lead to anemia and other complications.
Pathophysiology[edit]
The exact cause of multifocal lymphangioendotheliomatosis is unknown. It is believed to involve abnormal proliferation of lymphatic endothelial cells, leading to the formation of vascular lesions. The condition is not inherited in a simple Mendelian fashion, and no specific genetic mutations have been consistently identified.
Diagnosis[edit]
Diagnosis of multifocal lymphangioendotheliomatosis is primarily clinical, based on the characteristic appearance of skin lesions and associated symptoms. A biopsy of the lesions can confirm the diagnosis by revealing the presence of abnormal lymphatic vessels. Imaging studies, such as MRI or CT scan, may be used to assess the extent of internal involvement.
Management[edit]
There is no definitive cure for multifocal lymphangioendotheliomatosis. Management is supportive and focuses on controlling symptoms. Treatment options may include:
- Corticosteroids to reduce inflammation
- Beta-blockers such as propranolol to manage vascular lesions
- Blood transfusions for severe anemia
- Endoscopy and other interventions for gastrointestinal bleeding
Prognosis[edit]
The prognosis for individuals with multifocal lymphangioendotheliomatosis varies. Some patients may experience spontaneous regression of skin lesions, while others may have persistent or progressive disease. Complications such as severe anemia or heart failure can significantly impact quality of life and overall prognosis.
Also see[edit]
NIH genetic and rare disease info[edit]
Multifocal lymphangioendotheliomatosis is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - Multifocal lymphangioendotheliomatosis
|